Lv1
20 积分 2025-01-23 加入
Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients
8天前
已完结
Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients
8天前
已完结
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
10天前
已完结
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
10天前
已完结
And Still They Come Over Troubled Waters: Can Asia’s Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC
13天前
已完结
Aumolertinib is effective in NSCLC
13天前
已完结
Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants
14天前
已完结
A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
14天前
已完结
Determining the optimal dose in the development of anticancer agents
15天前
已完结
Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
15天前
已完结
皖公网安备34019202002308
